Question Everything. See who's reporting it.

Moderna’s melanoma vaccine shows promise despite stock plunge

Source: NBC News

The story in brief

A personalized mRNA vaccine for late-stage melanoma showed promise in reducing cancer recurrence, with side effects similar to Covid vaccines. However, investors reacted negatively to leaked findings, causing Moderna’s stock to drop. Results will be presented at the European Society for Medical Oncology meeting in Madrid.

3 outletsSee what the other 2 outlets said

NEWXFree on Android and iPhone. Open in NEWX